Pacific Biosciences Improves Key Applications on the Sequel System with New Chemistry and Software Release
January 09 2017 - 7:30AM
Pacific Biosciences of California, Inc. (Nasdaq:PACB) today
announced a new version of chemistry (V2) and software (V4) for the
Sequel™ System. The new release improves the system’s ability to
support important applications such as structural variant detection
and targeted sequencing
— including metagenomics,
minor variant detection and isoform sequencing
— by
achieving mean read lengths of 10-15 kb, with half of the data in
reads > 20 kb, and throughput from 5-8 Gb. In addition to these
applications, the high consensus accuracy, uniform coverage, and
long read lengths inherent to the Sequel System continue to make it
ideal for applications such as de novo genome assembly.
The Sequel System is PacBio’s latest platform based on its
Single Molecule, Real-Time (SMRT®) Sequencing technology. Since the
launch of the system in fall of 2015, PacBio has installed more
than 110 Sequel Systems globally. The latest release includes a new
version of the consumable SMRT Cells that is tuned for the new
sequencing chemistry kits. The company has also made updates to its
base calling algorithm that increase accuracy, and added new
features in the Sequel System software package designed for
clinical research applications. The V2 chemistry and V4 software
updates will be available on January 23, 2017.
This release improves users’ ability to perform low-fold
structural variant detection and key targeted sequencing
applications. For structural variant detection, they can now
accomplish the same or better quality of results for structural
variant analysis using, on average, half the number of SMRT Cells
compared to the previously available chemistry. Long read lengths
provided by the new chemistry also enable the detection of
larger-scale structural variants, in particular there is a 3-fold
increase in sensitivity of insertions over 5 kb. For targeted
sequencing, the new chemistry and the software gives users more
flexibility. For example, for minor variant detection, customers
can either gain detection sensitivity or reduce cost per sample
with increased sample multiplexing.
“This release is part of our continued commitment to increasing
the performance of the Sequel System, and we are very pleased with
the data we are seeing both internally and in beta-test customers’
hands,” said Kevin Corcoran, Senior Vice President of Market
Development for Pacific Biosciences. “We are focused on improving
the key applications that our customers care about and where SMRT
Sequencing provides unique advantages. For example, by
increasing throughput, we are making de novo genome assembly
projects more cost effective.”
More information about Sequel is available at:
http://www.pacb.com/sequel/.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
offers sequencing systems to help scientists resolve genetically
complex problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences’ products enable: de novo
genome assembly to finish genomes in order to more fully identify,
annotate and decipher genomic structures; full-length transcript
analysis to improve annotations in reference genomes, characterize
alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and real-time kinetic information
for epigenome characterization. Pacific Biosciences’ technology
provides high accuracy, ultra-long reads, uniform coverage, and is
the only DNA sequencing technology that provides the ability to
simultaneously detect epigenetic changes. PacBio® sequencing
systems, including consumables and software, provide a simple,
fast, end-to-end workflow for SMRT Sequencing. More information is
available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to future availability, uses, quality or
performance of, or benefits of using, products or technologies, and
other future events. You should not place undue reliance on
forward-looking statements because they involve known and unknown
risks, uncertainties, changes in circumstances and other factors
that are, in some cases, beyond Pacific Biosciences’ control and
could cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Factors that could materially affect actual
results can be found in Pacific Biosciences’ most recent filings
with the Securities and Exchange Commission, including Pacific
Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption “Risk Factors.”Pacific
Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Sep 2023 to Sep 2024